MannKind Q1: Afrezza net revenue $9.8M (+21% YoY); net loss $26.0M; cash $233M

MANNKIND CORP

2023-Q1 EPS reported -$0.10 revenue$11,992,000

Afrezza net revenue $9.8M, up 21% vs Q1 2021; gross margin improved to 77% from 47%.
Net loss $26.0M ($0.10 per share) vs $12.9M ($0.05) in Q1 2021, driven by lower collaboration revenue.
Cash and investments $233.0M at March 31, 2022; Tyvaso DPI PDUFA action date expected May 2022.
Collaborations & services revenue $2.2M, down $7.2M due to completion of R&D services for United Therapeutics.
Deferred revenue from commercial supply agreement with United Therapeutics increased to $25.7M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.